JP2004509952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509952A5 JP2004509952A5 JP2002531106A JP2002531106A JP2004509952A5 JP 2004509952 A5 JP2004509952 A5 JP 2004509952A5 JP 2002531106 A JP2002531106 A JP 2002531106A JP 2002531106 A JP2002531106 A JP 2002531106A JP 2004509952 A5 JP2004509952 A5 JP 2004509952A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- morpholin
- acetamide
- dichlorobenzyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 149
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 141
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 103
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 50
- -1 NR13 Chemical compound 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 26
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 8
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- MKCWTWOIIWRROF-UHFFFAOYSA-N 1-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzotriazole-5-carboxylic acid Chemical compound OC(=O)c1ccc2n(CC(=O)NCC3CN(Cc4ccc(Cl)c(Cl)c4)CCO3)nnc2c1 MKCWTWOIIWRROF-UHFFFAOYSA-N 0.000 description 1
- JYFNSZDTDYRIHG-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound ClC1=CC=C(Cl)C(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 JYFNSZDTDYRIHG-UHFFFAOYSA-N 0.000 description 1
- JYJSYZYBAVZUHV-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C(=CC=CC=2Cl)Cl)OCC1 JYJSYZYBAVZUHV-UHFFFAOYSA-N 0.000 description 1
- LZKQBIBTGJUICE-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C(=CC=CC=2)Cl)OCC1 LZKQBIBTGJUICE-UHFFFAOYSA-N 0.000 description 1
- UIZQMDGRYJFZQK-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C=C(Cl)C(Cl)=CC=2)OCC1 UIZQMDGRYJFZQK-UHFFFAOYSA-N 0.000 description 1
- LDDDEDCDPPPQFT-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound ClC1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 LDDDEDCDPPPQFT-UHFFFAOYSA-N 0.000 description 1
- KQJLAVQBOMJGFC-UHFFFAOYSA-N 2-(4-bromo-3,5-dimethylpyrazol-1-yl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound CC1=C(Br)C(C)=NN1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 KQJLAVQBOMJGFC-UHFFFAOYSA-N 0.000 description 1
- JHMXPUCRTAYCDZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 JHMXPUCRTAYCDZ-UHFFFAOYSA-N 0.000 description 1
- UQVDLUQACOPECV-UGNFMNBCSA-N 2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-n-[[(2s)-4-(1-phenylethyl)morpholin-2-yl]methyl]acetamide Chemical compound C([C@@H]1OCCN(C1)C(C)C=1C=CC=CC=1)NC(=O)CC(=C(O1)C)N=C1C1=CC=C(F)C=C1 UQVDLUQACOPECV-UGNFMNBCSA-N 0.000 description 1
- WISMQAZNLJWJDU-NRFANRHFSA-N 2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-n-[[(2s)-4-[2-(4-fluorophenyl)-2-oxoethyl]morpholin-2-yl]methyl]acetamide Chemical compound C([C@@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC(F)=CC=2)N1CC(=O)C1=CC=C(F)C=C1 WISMQAZNLJWJDU-NRFANRHFSA-N 0.000 description 1
- OUXCRTKKJLVYBY-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 OUXCRTKKJLVYBY-UHFFFAOYSA-N 0.000 description 1
- ANCDHBXLDURTHN-UHFFFAOYSA-N 2-phenoxypropanamide Chemical compound NC(=O)C(C)OC1=CC=CC=C1 ANCDHBXLDURTHN-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- NHOITSTWCDUYAQ-QFIPXVFZSA-N 3-[2-[[(2s)-4-[(3-chlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-cyclopropylbenzamide Chemical compound ClC1=CC=CC(CN2C[C@H](CNC(=O)CC=3C=C(C=CC=3)C(=O)NC3CC3)OCC2)=C1 NHOITSTWCDUYAQ-QFIPXVFZSA-N 0.000 description 1
- ROBASCRROMVVND-SFHVURJKSA-N 3-[2-[[(2s)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-cyclopropylbenzamide Chemical compound S1C(Cl)=CC=C1CN1C[C@H](CNC(=O)CC=2C=C(C=CC=2)C(=O)NC2CC2)OCC1 ROBASCRROMVVND-SFHVURJKSA-N 0.000 description 1
- FTTPPVDVQPABRK-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 FTTPPVDVQPABRK-UHFFFAOYSA-N 0.000 description 1
- OJQGJGGPRSOVAM-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 OJQGJGGPRSOVAM-UHFFFAOYSA-N 0.000 description 1
- LJJGPPAFVHTUBZ-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 LJJGPPAFVHTUBZ-UHFFFAOYSA-N 0.000 description 1
- HWXSNLXRQOVRFJ-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzotriazole-5-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC=C2N=NN1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 HWXSNLXRQOVRFJ-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- CPTHFDQFZLWHSN-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 CPTHFDQFZLWHSN-UHFFFAOYSA-N 0.000 description 1
- YIMJPSBXMJBMCH-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 YIMJPSBXMJBMCH-UHFFFAOYSA-N 0.000 description 1
- RBCYAHOMYPCVHJ-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 RBCYAHOMYPCVHJ-UHFFFAOYSA-N 0.000 description 1
- UVGVPEKRWGKGKZ-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-propan-2-ylbenzamide Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 UVGVPEKRWGKGKZ-UHFFFAOYSA-N 0.000 description 1
- QAAZDCGSSWACNU-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 QAAZDCGSSWACNU-UHFFFAOYSA-N 0.000 description 1
- XJCCVBPRDUAFBK-NRFANRHFSA-N 4-[4-[2-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-5-methyl-1,3-oxazol-2-yl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C1=NC(CC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C(C)O1 XJCCVBPRDUAFBK-NRFANRHFSA-N 0.000 description 1
- PTUBNTVRWLDJBP-CRAIPNDOSA-N ClC=1C=C(CN2C[C@H](OC[C@H]2C)CNC(CC2=CC=CC=C2)=O)C=CC=1Cl Chemical compound ClC=1C=C(CN2C[C@H](OC[C@H]2C)CNC(CC2=CC=CC=C2)=O)C=CC=1Cl PTUBNTVRWLDJBP-CRAIPNDOSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CODAIKLZEIPJNA-UHFFFAOYSA-N N-(5-phenyltetrazol-2-yl)acetamide Chemical compound C(C)(=O)NN1N=C(N=N1)C1=CC=CC=C1 CODAIKLZEIPJNA-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HFUNQLVTMBETML-UHFFFAOYSA-N methyl 2-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzotriazole-5-carboxylate Chemical compound N1=C2C=C(C(=O)OC)C=CC2=NN1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 HFUNQLVTMBETML-UHFFFAOYSA-N 0.000 description 1
- BTLXBJBBTNKZOW-UHFFFAOYSA-N methyl 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzoate Chemical compound COC(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 BTLXBJBBTNKZOW-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- PIZQTSMNGFLAOU-UHFFFAOYSA-N n-[3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]phenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 PIZQTSMNGFLAOU-UHFFFAOYSA-N 0.000 description 1
- IXFWJWZFPVVHBE-UHFFFAOYSA-N n-[4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]phenyl]-2-methylpropanamide Chemical compound C1=CC(NC(=O)C(C)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 IXFWJWZFPVVHBE-UHFFFAOYSA-N 0.000 description 1
- MIJQXFRSAOOOTI-QGZVFWFLSA-N n-[[(2r)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylsulfonylphenyl)acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)NC[C@H]1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 MIJQXFRSAOOOTI-QGZVFWFLSA-N 0.000 description 1
- FGUIUYGIZLOOHE-LJQANCHMSA-N n-[[(2r)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide Chemical compound C([C@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC=CC=2)N1CC1=CC=C(Cl)C(Cl)=C1 FGUIUYGIZLOOHE-LJQANCHMSA-N 0.000 description 1
- VOSAXWZFOHNAKO-MRXNPFEDSA-N n-[[(2r)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methyl]-2-[3-(methanesulfonamido)phenyl]acetamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC(=O)NC[C@H]2OCCN(CC=3SC(Cl)=CC=3)C2)=C1 VOSAXWZFOHNAKO-MRXNPFEDSA-N 0.000 description 1
- PTUBNTVRWLDJBP-MAUKXSAKSA-N n-[[(2r,5s)-4-[(3,4-dichlorophenyl)methyl]-5-methylmorpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C([C@H]1OC[C@@H](N(C1)CC=1C=C(Cl)C(Cl)=CC=1)C)NC(=O)CC1=CC=CC=C1 PTUBNTVRWLDJBP-MAUKXSAKSA-N 0.000 description 1
- LHEXVCZVAZHCCT-IBGZPJMESA-N n-[[(2s)-4-(2,1,3-benzoxadiazol-5-ylmethyl)morpholin-2-yl]methyl]-2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]acetamide Chemical compound N=1C(CC(=O)NC[C@@H]2OCCN(CC3=CC4=NON=C4C=C3)C2)=C(C)OC=1C1=CC=C(F)C=C1 LHEXVCZVAZHCCT-IBGZPJMESA-N 0.000 description 1
- MIJQXFRSAOOOTI-KRWDZBQOSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylsulfonylphenyl)acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)NC[C@@H]1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 MIJQXFRSAOOOTI-KRWDZBQOSA-N 0.000 description 1
- FGUIUYGIZLOOHE-IBGZPJMESA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide Chemical compound C([C@@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC=CC=2)N1CC1=CC=C(Cl)C(Cl)=C1 FGUIUYGIZLOOHE-IBGZPJMESA-N 0.000 description 1
- IRPHGDKGHNCXIA-HNNXBMFYSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-4-methylpentanamide Chemical compound C1CO[C@@H](CNC(=O)CCC(C)C)CN1CC1=CC=C(Cl)C(Cl)=C1 IRPHGDKGHNCXIA-HNNXBMFYSA-N 0.000 description 1
- STEXWNBVZFVLID-ZDUSSCGKSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]cyclopropanecarboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C[C@H](CNC(=O)C2CC2)OCC1 STEXWNBVZFVLID-ZDUSSCGKSA-N 0.000 description 1
- DXUSLRXHNWADRT-AWEZNQCLSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]pentanamide Chemical compound C1CO[C@@H](CNC(=O)CCCC)CN1CC1=CC=C(Cl)C(Cl)=C1 DXUSLRXHNWADRT-AWEZNQCLSA-N 0.000 description 1
- VOSAXWZFOHNAKO-INIZCTEOSA-N n-[[(2s)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methyl]-2-[3-(methanesulfonamido)phenyl]acetamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC(=O)NC[C@@H]2OCCN(CC=3SC(Cl)=CC=3)C2)=C1 VOSAXWZFOHNAKO-INIZCTEOSA-N 0.000 description 1
- MMUXUFDKBNTQRW-QFIPXVFZSA-N n-[[(2s)-4-[2-(3-chlorophenoxy)ethyl]morpholin-2-yl]methyl]-2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]acetamide Chemical compound C([C@@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC(F)=CC=2)N1CCOC1=CC=CC(Cl)=C1 MMUXUFDKBNTQRW-QFIPXVFZSA-N 0.000 description 1
- IHTMDVDZFSXHBH-BEFAXECRSA-N n-[[(2s,5r)-4-[(2,5-dichlorophenyl)methyl]-5-methylmorpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C([C@@H]1OC[C@H](N(C1)CC=1C(=CC=C(Cl)C=1)Cl)C)NC(=O)CC1=CC=CC=C1 IHTMDVDZFSXHBH-BEFAXECRSA-N 0.000 description 1
- PTUBNTVRWLDJBP-QAPCUYQASA-N n-[[(2s,5r)-4-[(3,4-dichlorophenyl)methyl]-5-methylmorpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C([C@@H]1OC[C@H](N(C1)CC=1C=C(Cl)C(Cl)=CC=1)C)NC(=O)CC1=CC=CC=C1 PTUBNTVRWLDJBP-QAPCUYQASA-N 0.000 description 1
- KHRWSTKNTPHEIX-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 KHRWSTKNTPHEIX-UHFFFAOYSA-N 0.000 description 1
- SASFTZBPEAQHTN-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(2-phenyl-1,3-thiazol-4-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2N=C(SC=2)C=2C=CC=CC=2)OCC1 SASFTZBPEAQHTN-UHFFFAOYSA-N 0.000 description 1
- FCLWTLISXFHQEU-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(3,4-difluorophenyl)acetamide Chemical compound C1=C(F)C(F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 FCLWTLISXFHQEU-UHFFFAOYSA-N 0.000 description 1
- ROLSNQHXWUPMFL-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 ROLSNQHXWUPMFL-UHFFFAOYSA-N 0.000 description 1
- IZOYGZNMKXARJZ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(3-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 IZOYGZNMKXARJZ-UHFFFAOYSA-N 0.000 description 1
- DNZXWUUNTDBKFN-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-fluoro-2-methylphenyl)acetamide Chemical compound CC1=CC(F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 DNZXWUUNTDBKFN-UHFFFAOYSA-N 0.000 description 1
- QSVIELROKCBLGE-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 QSVIELROKCBLGE-UHFFFAOYSA-N 0.000 description 1
- FWZOQJCUPXLSIO-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 FWZOQJCUPXLSIO-UHFFFAOYSA-N 0.000 description 1
- GLLIZTBQMBJXFI-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 GLLIZTBQMBJXFI-UHFFFAOYSA-N 0.000 description 1
- KZFUBTRBLPLQIJ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylsulfanylphenyl)acetamide Chemical compound C1=CC(SC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 KZFUBTRBLPLQIJ-UHFFFAOYSA-N 0.000 description 1
- FRZLJHUTGANTLG-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-nitrophenyl)acetamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 FRZLJHUTGANTLG-UHFFFAOYSA-N 0.000 description 1
- GRDFSBFJZSAGAC-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide Chemical compound C12=CC(OC)=CC=C2NC(C)=C1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 GRDFSBFJZSAGAC-UHFFFAOYSA-N 0.000 description 1
- USILSJUHUPHFFZ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-1-phenylpyrazol-4-yl)acetamide Chemical compound C1=NN(C=2C=CC=CC=2)C(C)=C1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 USILSJUHUPHFFZ-UHFFFAOYSA-N 0.000 description 1
- FGUIUYGIZLOOHE-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 FGUIUYGIZLOOHE-UHFFFAOYSA-N 0.000 description 1
- XVWANSPPDJZSCG-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(furan-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2OC=CC=2)OCC1 XVWANSPPDJZSCG-UHFFFAOYSA-N 0.000 description 1
- COIFKIVUCMELOL-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]acetamide Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 COIFKIVUCMELOL-UHFFFAOYSA-N 0.000 description 1
- XOUDBQNDBJIUDX-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-[3-[methyl(methylsulfonyl)amino]phenyl]acetamide Chemical compound CS(=O)(=O)N(C)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 XOUDBQNDBJIUDX-UHFFFAOYSA-N 0.000 description 1
- AXAYMEOPQHXZBZ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-[4-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 AXAYMEOPQHXZBZ-UHFFFAOYSA-N 0.000 description 1
- HMCGXXKIOWCREI-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C=CC=CC=2)OCC1 HMCGXXKIOWCREI-UHFFFAOYSA-N 0.000 description 1
- ZMGHLJFRSADFNU-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-thiophen-3-ylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC2=CSC=C2)OCC1 ZMGHLJFRSADFNU-UHFFFAOYSA-N 0.000 description 1
- CVXRGDUVLQHQIF-UHFFFAOYSA-N n-[[4-[(3-fluorophenyl)methyl]morpholin-2-yl]methyl]-2-[4-(methanesulfonamido)phenyl]acetamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(F)C=CC=2)C1 CVXRGDUVLQHQIF-UHFFFAOYSA-N 0.000 description 1
- LZTXBUAOAXGSET-UHFFFAOYSA-N n-[[4-[3-(3,4-dichlorophenyl)propyl]morpholin-2-yl]methyl]-2-phenoxyacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CCCN1CC(CNC(=O)COC=2C=CC=CC=2)OCC1 LZTXBUAOAXGSET-UHFFFAOYSA-N 0.000 description 1
- PIGPZJQOGGOVGR-UHFFFAOYSA-N n-[[4-[3-(3,4-dichlorophenyl)propyl]morpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CCCN1CC(CNC(=O)CC=2C=CC=CC=2)OCC1 PIGPZJQOGGOVGR-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023902.0 | 2000-09-29 | ||
| GB0023902A GB0023902D0 (en) | 2000-09-29 | 2000-09-29 | Therapeutically useful compounds |
| GB0107644.7 | 2001-03-27 | ||
| GB0107644A GB0107644D0 (en) | 2001-03-27 | 2001-03-27 | Therapeutically useful compounds |
| PCT/GB2001/004345 WO2002026722A1 (en) | 2000-09-29 | 2001-09-28 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004509952A JP2004509952A (ja) | 2004-04-02 |
| JP2004509952A5 true JP2004509952A5 (enExample) | 2008-11-13 |
| JP5089846B2 JP5089846B2 (ja) | 2012-12-05 |
Family
ID=26245078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002531106A Expired - Lifetime JP5089846B2 (ja) | 2000-09-29 | 2001-09-28 | 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7101882B2 (enExample) |
| EP (1) | EP1324990B1 (enExample) |
| JP (1) | JP5089846B2 (enExample) |
| KR (1) | KR20030031198A (enExample) |
| CN (1) | CN1678594A (enExample) |
| AR (1) | AR035205A1 (enExample) |
| AU (1) | AU2001290143A1 (enExample) |
| BR (1) | BR0114323A (enExample) |
| CA (1) | CA2423251A1 (enExample) |
| CZ (1) | CZ20031195A3 (enExample) |
| ES (1) | ES2527688T3 (enExample) |
| HU (1) | HUP0302302A2 (enExample) |
| IL (1) | IL155093A0 (enExample) |
| MX (1) | MXPA03002814A (enExample) |
| NO (1) | NO20031442L (enExample) |
| NZ (1) | NZ525056A (enExample) |
| PL (1) | PL362711A1 (enExample) |
| WO (1) | WO2002026722A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035205A1 (es) * | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
| EP1353918B1 (en) * | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| GB0207449D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| GB0208158D0 (en) * | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0207443D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0211759D0 (en) * | 2002-05-22 | 2002-07-03 | Glaxo Group Ltd | Novel compounds |
| GB0212357D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| GB0212355D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| CA2579207C (en) * | 2004-09-08 | 2011-10-18 | Mitsubishi Pharma Corporation | Morpholine compound |
| JP5281291B2 (ja) | 2005-01-10 | 2013-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US20090118288A1 (en) * | 2005-07-21 | 2009-05-07 | Astrazeneca Ab | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor |
| EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
| MX2009003080A (es) | 2006-09-22 | 2009-04-02 | Novartis Ag | Compuestos organicos heterociclicos. |
| AU2007336238A1 (en) | 2006-12-20 | 2008-06-26 | Novartis Ag | 2-substituted 5-membered heterocycles as SCD inhibitors |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ，エルエルシー． | ５−リポキシゲナーゼ活性化タンパク質阻害剤 |
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| EP2280946B1 (en) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| KR101036913B1 (ko) * | 2008-12-26 | 2011-05-25 | 주식회사 포스코 | 고로의 머드건과 노즐팁 사이의 틈새 메움용 장치 및 방법 |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Ｉｔｋ阻害剤として使用されるピリミジン誘導体 |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| AU2010226604A1 (en) | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
| EP2411517A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| RS53830B1 (sr) | 2009-04-30 | 2015-06-30 | Glaxo Group Limited | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| HRP20151017T1 (hr) | 2010-09-08 | 2015-10-23 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida |
| EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| US20140335083A1 (en) * | 2011-12-01 | 2014-11-13 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| US9399637B2 (en) | 2014-03-28 | 2016-07-26 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| FR3022142B1 (fr) | 2014-06-16 | 2019-07-12 | Universite Paul Sabatier - Toulouse Iii | Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| EP3740468B1 (en) | 2018-01-20 | 2025-12-31 | Sunshine Lake Pharma Co., Ltd. | Substituted Aminopyrimidine Compounds and Methods of Use |
| CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
| CN118852047B (zh) * | 2024-07-09 | 2025-09-16 | 吉林修正药业新药开发有限公司 | 一种枸橼酸莫沙必利中间体制备方法和枸橼酸莫沙必利制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ284687B6 (cs) * | 1986-04-30 | 1999-02-17 | Dainippon Pharmaceutical Co., Ltd. | Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi |
| JPS63264467A (ja) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
| JPH01117882A (ja) | 1987-10-30 | 1989-05-10 | Dainippon Pharmaceut Co Ltd | 複素環式カルボン酸アミド誘導体 |
| JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
| JPH04247074A (ja) * | 1991-02-01 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | ４−モルホリノ安息香酸誘導体の製造法 |
| WO1995031431A1 (en) | 1994-05-18 | 1995-11-23 | Nisshin Flour Milling Co., Ltd. | Novel diaminomethylidene derivative |
| WO1995031442A1 (fr) * | 1994-05-18 | 1995-11-23 | Nisshin Flour Milling Co., Ltd. | Nouveau derive de pyrimidine |
| JPH11505815A (ja) | 1995-05-23 | 1999-05-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | （２−モルホリニルメチル）ベンズアミン誘導体 |
| DE19624704A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| JP2002512957A (ja) | 1998-04-27 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | Ｃｃｒ−３受容体アンタゴニスト |
| WO2000004003A1 (en) | 1998-07-14 | 2000-01-27 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027800A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| TR200101155T2 (tr) | 1998-11-17 | 2001-09-21 | F. Hoffmann-La Roche Ag | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III |
| BR9915520A (pt) | 1998-11-20 | 2001-07-17 | Hoffmann La Roche | Antagonistas receptores ccr-3 derivados de pirrolidina |
| ATE386720T1 (de) | 1998-11-20 | 2008-03-15 | Hoffmann La Roche | Piperidin ccr-3 rezeptor-hemmer |
| EP1067130A4 (en) | 1998-12-04 | 2004-02-11 | Toray Industries | TRIAZOLO DERIVATIVES, AND CHIMIOKIN INHIBITORS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT |
| US6331545B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | Heterocycyclic piperidines as modulators of chemokine receptor activity |
| HK1044282A1 (zh) | 1998-12-18 | 2002-10-18 | Bristol-Myers Squibb Pharma Company | 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物 |
| EP1140833A1 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| AU2057200A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU2482100A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
| US6303593B1 (en) | 1999-03-02 | 2001-10-16 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| EP1187810A2 (en) | 1999-05-25 | 2002-03-20 | Sepracor, Inc. | Heterocyclic analgesic compounds and their use |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| AR035205A1 (es) * | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
-
2001
- 2001-09-28 AR ARP010104602A patent/AR035205A1/es not_active Application Discontinuation
- 2001-09-28 US US10/381,767 patent/US7101882B2/en not_active Expired - Lifetime
- 2001-09-28 NZ NZ525056A patent/NZ525056A/en unknown
- 2001-09-28 IL IL15509301A patent/IL155093A0/xx unknown
- 2001-09-28 HU HU0302302A patent/HUP0302302A2/hu unknown
- 2001-09-28 WO PCT/GB2001/004345 patent/WO2002026722A1/en not_active Ceased
- 2001-09-28 CA CA002423251A patent/CA2423251A1/en not_active Abandoned
- 2001-09-28 KR KR10-2003-7004594A patent/KR20030031198A/ko not_active Withdrawn
- 2001-09-28 JP JP2002531106A patent/JP5089846B2/ja not_active Expired - Lifetime
- 2001-09-28 AU AU2001290143A patent/AU2001290143A1/en not_active Abandoned
- 2001-09-28 CN CNA018196365A patent/CN1678594A/zh active Pending
- 2001-09-28 MX MXPA03002814A patent/MXPA03002814A/es unknown
- 2001-09-28 ES ES01970023.6T patent/ES2527688T3/es not_active Expired - Lifetime
- 2001-09-28 PL PL01362711A patent/PL362711A1/xx not_active Application Discontinuation
- 2001-09-28 EP EP01970023.6A patent/EP1324990B1/en not_active Expired - Lifetime
- 2001-09-28 CZ CZ20031195A patent/CZ20031195A3/cs unknown
- 2001-09-28 BR BR0114323-9A patent/BR0114323A/pt not_active IP Right Cessation
-
2003
- 2003-03-27 US US10/509,519 patent/US20050222147A1/en not_active Abandoned
- 2003-03-28 NO NO20031442A patent/NO20031442L/no unknown
-
2005
- 2005-11-22 US US11/284,544 patent/US7560548B2/en not_active Expired - Lifetime
-
2009
- 2009-02-24 US US12/391,855 patent/US20090163495A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004509953A5 (enExample) | ||
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| RU2489426C2 (ru) | Производные аминопиразола | |
| JP2017538750A5 (enExample) | ||
| JP2022506445A5 (enExample) | ||
| US6150385A (en) | 1,3,4-thiadiazoles useful for the treatment of CMV infections | |
| JP2013516415A5 (enExample) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| RU2009109147A (ru) | Органические соединения | |
| JP2023542541A5 (enExample) | ||
| DE1283831T1 (de) | Inhibitoren der 11-beta-hydroxy-steroid-dehydrogenase des typs 1 | |
| JP2003534336A5 (enExample) | ||
| RU2009149696A (ru) | 5-замещенные индазолы в качестве ингибиторов киназы | |
| JP2006526656A5 (enExample) | ||
| JP2010516765A5 (enExample) | ||
| JP2009502948A5 (enExample) | ||
| JP2017523972A5 (enExample) | ||
| JP2019516737A5 (enExample) | ||
| RU2453544C3 (ru) | Фунгицидные азоциклические амиды | |
| RU2005109561A (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| RU2006145205A (ru) | Терапевтические соединения: пиридин в качестве каркаса | |
| RU2018112749A (ru) | Модуляторы индоламин-2,3-диоксигеназы | |
| RU2006125446A (ru) | Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение | |
| JP2010540462A5 (enExample) | ||
| JP2016523963A5 (enExample) |